Search Results
Your search for ,New matches 16922 pages
Showing 501 - 550NSCLC Trial Shows Radiation May Overcome Primary Resistance to Pembrolizumab
The addition of radiation may be able to surmount resistance to immunotherapy for some more immunologically “cold” tumors, as suggested by the findings of a study focused on the immunomodulatory effects of radiation in non–small cell lung cancers (NSCLCs). The research was recently published in...
American Cancer Society Names New CEO
The American Cancer Society (ACS) and its advocacy affiliate the American Cancer Society Cancer Action Network (ACS CAN) have announced Shane Jacobson as their Chief Executive Officer, effective August 12, 2025. He steps into the role following Wayne A.I. Frederick, MD, MBA, FACS, who has served as ...
Short-Term Hormonal Treatment Offers Early Insight Into Tumor Behavior and Resistance for ER+/HER2+ Breast Cancer
How ER-positive, HER2-positive breast cancer tumors respond to a short course of hormonal treatment may help to determine whether more aggressive treatment options are necessary for each patient or not, according to translational findings published in eBioMedicine. Tumor subtype changes after 2...
Evaluation of Racial Classification Standards in U.S. Cancer Surveillance Systems
Despite multiple federal updates to race data collection standards, researchers have found persistent discrepancies in how cancer incidence and mortality rates are recorded for racial minorities—particularly multiracial individuals. A recent study in Cancer highlights how evolving definitions of...
CBO Report Finds Federal Cuts to NIH Would Threaten New Drug Development and Innovation
A new report from the nonpartisan Congressional Budget Office (CBO) has found that proposed cuts at the National Institutes of Health (NIH) could lower the number of new drugs that come to market in the next 3 decades. The report comes as Congress considers President Trump’s proposed budget for...
Alcohol-Associated Cancer Death Rates Are Climbing
Alcohol-associated cancer deaths have doubled in the United States, disproportionately affecting men and those aged 55 or older, according to the results of an observational study presented at the 2025 ASCO Annual Meeting.1 Over the study period of 30 years, proportional mortality rates increased...
DREAMM-7 Analysis Compares Survival Outcomes Between Triplet Regimens for Relapsed or Refractory Multiple Myeloma
In an analysis from the phase III DREAMM-7 trial reported in The Lancet Oncology, Hungria et al compared survival outcomes with belantamab mafodotin, bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed or refractory multiple myeloma...
Real-World Data Show COVID-19 Boosters Offer Protection for Patients With Cancer
COVID-19 vaccine boosters for adult patients with cancer helped to keep these patients from being hospitalized or admitted to intensive care units due to severe COVID-19 infections, according to the results of a retrospective cohort study published in JAMA Oncology. “Cancer patients are a...
Outcomes Support CAR T-Cell Therapy Use in Elderly Patients With B-Cell Lymphomas
Patients in their 80s or older with B-cell lymphomas are able to receive chimeric antigen receptor (CAR) T-cell therapy safely, results of a multicenter retrospective study published in Bone Marrow Transplantation showed. These patients are usually not eligible for clinical trials of CAR T-cell...
Classifying Pancreatic Cysts Using AI Models
In a proof-of-concept study published in the Journal of the American College of Surgeons, researchers investigated whether artificial intelligence (AI) models such as ChatGPT-4 can be used to accurately extract and classify diagnostic data from radiologic imaging reports of pancreatic cysts. The...
Survey Highlights Top Anxiety Points for Caregivers After a Cancer Diagnosis
New survey findings highlight that the anxiety caused by a cancer diagnosis extends far beyond just the patient diagnosed. The emotional impact is shared by caregivers and loved ones, with stress, grief, and worry over treatments, pain, and life expectancy weighing heavily on these individuals,...
Can Use of Aprepitant During Chemotherapy Improve Triple-Negative Breast Cancer Outcomes?
Aprepitant, a commonly used antiemetic, led to improvements in patient outcomes when given during chemotherapy treatment for patients with non-luminal early breast cancer. Patients showed better prognoses and survival advantages, particularly among those with triple-negative breast cancer. Study...
Lisocabtagene Maraleucel as Second-Line Therapy in Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up
As reported in the Journal of Clinical Oncology by Kamdar et al, the 3-year follow-up of the phase III TRANSFORM trial showed that lisocabtagene maraleucel (liso-cel) maintained superior efficacy vs standard of care (SOC) in second-line treatment of relapsed/refractory large B-cell lymphoma (LBCL). ...
People With Acromegaly Face Elevated Cancer Risk, Study Finds
A new study presented at the 2025 Annual Meeting of the Endocrine Society (ENDO 2025) found that individuals with acromegaly—an endocrine disorder caused by excessive growth hormone secretion—are at a significantly heightened risk of developing various types of cancer, often at younger ages...
New Guidelines on Comprehensive Biomarker Testing of Bronchoscopic Biopsies
Linear endobronchial guided sampling of accessible mediastinal lesions is well established as a first-choice modality for lung cancer mediastinal staging. Parenchymal lung lesions, however, are routinely accessed by either a percutaneous (CT-guided) or a bronchoscopic approach. There have been few...
Sharp Rise in Obesity-Linked Cancer Mortality Highlights Geographic and Demographic Gaps
Obesity-related cancer deaths have tripled in the United States over the past 2 decades, with significant disparities seen by gender, race, age, and geography, according to findings from a national epidemiological analysis presented at ENDO 2025, the annual meeting of The Endocrine Society...
New Research Offers Reassurance About Localized Prostate Cancer Prognosis
A recent study out of Sweden found that people diagnosed with nonmetastatic low-risk prostate cancer later in life were 90% more likely to survive their cancer for their remaining life expectancy if they were treated according to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Of...
Chemoimmunotherapy for Advanced BTC: 3-Year Overall Survival Update From the TOPAZ Trial
In a follow-up analysis of the pivotal TOPAZ-1 study, which established the combination of the PD-L1 inhibitor durvalumab plus gemcitabine and cisplatin as the first-line treatment for advanced biliary tract cancer (BTC), researchers have shown that after 3 years, more than twice as many study...
RP1 Plus Nivolumab in Anti–PD-1–Resistant Advanced Melanoma
When combined with nivolumab, RP1 (vusolimogene oderparepvec), a genetically engineered herpes simplex virus type 1–based oncolytic immunotherapy, induced deep and durable systemic responses in patients with advanced melanoma who have failed to respond to prior anti–PD-1 therapy, according to...
A Young Hematologist’s Take on ICML 2025
From Dr. Bruce Cheson’s electric speech on how it all started with pentostatin in hairy cell leukemia, to the introduction of bendamustine in indolent lymphoma, to the development of R-squared (an innovative chemotherapy-free approach to treating lymphoma)—the nostalgia at the International...
AJCC Guideline Reassessment Aims to Improve HPV-Positive Throat Cancer Staging
An update of staging guidelines from the American Joint Committee on Cancer (AJCC) for human papillomavirus (HPV)-positive throat cancer—now more common in the United States than cervical cancer, according to the American Cancer Society—aims to make treatment of early-stage disease more consistent...
Ruxolitinib for Steroid-Refractory or -Dependent Chronic Graft-vs-Host Disease
In the 3-year final analysis of the phase III REACH3 trial reported in the Journal of Clinical Oncology, Zeiser et al compared the use of ruxolitinib vs best available therapy (BAT) in terms of failure-free survival and duration of response in patients with steroid-refractory or -dependent chronic...
Women Over the Age of 65 Still at Heightened Risk of HPV-Related Cervical Cancer
Women aged 65 years and older are still at a heightened risk of cervical cancer caused by human papillomavirus (HPV), suggest the findings of a large observational Chinese study published by Ye et al in Gynecology and Obstetrics Clinical Medicine. Most guidelines currently recommend discontinuing...
Corticosteroids May Limit Efficacy of Immunotherapy in Patients With NSCLC
Corticosteroids, which are commonly prescribed to alleviate cancer-related symptoms in patients with non–small cell lung cancer (NSCLC) treated with immunotherapy, may be the reason certain immunotherapies fail in treating the disease, according to new research published by Polyakov et al in Cancer ...
The Future of Cell Therapy: Optimizing the CAR to the Disease in B-Cell Malignancies
Over the past 20 years, increased understanding of the biological mechanism of disease has led to improved treatment options for all malignancies. Within each disease subtype, we have molecularly characterized tumors and developed specific treatment algorithms to optimize patient outcomes. Among...
Study Supports Multi-Contaminant Water Treatment to Reduce Cancer Risk
Treating drinking water for multiple contaminants, especially arsenic and chromium-6, could prevent more than 50,000 cancer cases in the United States, according to the results of a study by the Environmental Working Group that was published in Environmental Research. Study findings highlighted...
Subsequent Neoplasm Risk Among Childhood Cancer Survivors: Effect of BMI and Physical Activity
In a study reported in JAMA Oncology, Joffe et al examined the association of high body mass index (BMI) and low physical activity with increased risk of subsequent neoplasms among childhood cancer survivors. Study Details The study involved data on 5-year survivors of childhood cancers diagnosed...
Nivolumab or Brentuximab Vedotin With AVD in Older Patients With Advanced Classical Hodgkin Lymphoma
In a subset analysis from the phase III SWOG S1826 trial reported in the Journal of Clinical Oncology, Rutherford et al compared the survival outcomes of nivolumab plus AVD (doxorubicin, vinblastine, dacarbazine; N-AVD) vs brentuximab vedotin plus AVD (BV-AVD) in patients with advanced-stage...
Adult Survivors of Childhood Cancer May Be at Increased Risk of Severe COVID-19 Infection
People who have survived cancer as children may be at a higher risk of developing severe COVID-19 infection—even decades after their cancer diagnosis, according to results published by Louro et al in The Lancet Regional Health – Europe. Thanks to medical advances, more and more children are...
Survival Disparities Rise in Patients With Advanced Cancer Depending on Whether They Have Insurance to Cover Immune Checkpoint Inhibitors
A study led by researchers at the American Cancer Society examining the association between the introduction of immune checkpoint inhibitors (ICIs) and changes in survival disparities by health insurance coverage among patients with newly diagnosed stage IV melanoma, non–small cell lung cancer...
Preclinical Leukemia Chip Platform Improves Evaluation of CAR T-Cell Therapies
Investigators have bioengineered an organotypic immunocompetent chip—a laboratory device that combines the physical structure of human leukemia bone marrow and a functioning immune system—to empower real-time spatiotemporal monitoring of CAR-T cell functionality for leukemias. The preclinical...
Bevacizumab Plus Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer
In a National Cancer Institute phase II trial reported in The New England Journal of Medicine, Srinivasan et al investigated whether the monoclonal antibody bevacizumab in combination with the EGFR inhibitor erlotinib showed activity in patients with advanced hereditary leiomyomatosis and renal...
PPP2R1A Mutations Linked to Improved Immunotherapy Outcomes in Ovarian Clear Cell Carcinoma
Patients with ovarian clear cell carcinoma harboring PPP2R1A mutations showed significantly improved survival when treated with immunotherapy compared with those without PPP2R1A mutations, according to study findings published in Nature. Preclinical findings from the study also suggested that...
Study Reveals Long-Term Consequences of Chemotherapy on Healthy Blood Cells
Many cytotoxic chemotherapy agents have long-term biological consequences, including premature aging of the cell population structure of healthy blood, the results of a study of the genetic effects of chemotherapy showed. These findings published in Nature Genetics may help to guide future...
Can Hormone Therapy Affect Breast Cancer Risk in Younger Women?
Investigators have found that two common types of hormone therapy may alter breast cancer risk in women before age 55. Women treated with unopposed estrogen hormone therapy (E-HT) were less likely to develop the disease than those who did not use this type of hormone therapy. Additionally, women...
Uterine Cancer Incidence and Mortality Rates Projected to Rise Substantially by 2050
Uterine cancer is the fourth most common cancer diagnosed in women in the United States, with about 69,120 new cases and nearly 14,000 deaths from the disease expected this year. Black women experience a twice as high mortality rate compared with women of other races and ethnicities, and that...
AI-Enhanced PACT as a Noninvasive Breast Imaging Alternative
Panoramic photoacoustic computed tomography (PACT) with machine learning assistance could be a safe, noninvasive, and sensitive alternative to mammography, ultrasound, and magnetic resonance imaging (MRI) for breast cancer screening, according to study results that were published in Nature...
utDNA May Help to Personalize Bladder Cancer Treatment
Results of a multi-institutional study published by St-Laurent et al in Science Direct revealed that testing urine-based tumor DNA (utDNA) may help to predict which patients with bladder cancer are at higher risk for recurrence after not responding to first-line treatment. The study analyzed utDNA...
Genitourinary Oncology Highlights: Treatment Advances in Renal Cell, Bladder, Urothelial, and Prostate Cancers
The 2025 ASCO Annual Meeting has officially concluded. Our sincere thanks to the global oncology community and ASCO for creating such a remarkable forum advancing cancer care. Here we highlight the most impactful updates in genitourinary tumors from this year’s meeting. Kidney Cancer: Long-Term...
ASTRO Updates Guideline on Radiation Therapy for High-Grade Diffuse Glioma
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) focuses on the use of radiation therapy for adults with World Health Organization (WHO) grade 4 diffuse gliomas, a category that includes some of the most common and most aggressive primary brain tumors. The...
Addition of Retifanlimab to First-Line Chemotherapy in Advanced Squamous Cell Carcinoma of the Anal Canal
In a phase III trial (POD1UM-303/InterAACT-2) reported in The Lancet, Rao et al investigated the survival benefit of adding the PD-1 inhibitor retifanlimab to carboplatin-paclitaxel in patients with locally recurrent or metastatic squamous cell carcinoma of the anal canal. Study Details In the...
Best Practice Recommendations for Clinical Homologous Recombination Deficiency Testing
The Association for Molecular Pathology has introduced best practice recommendations for clinical laboratories developing and performing homologous recombination deficiency testing, according to new guidelines published by Hsiao et al in The Journal of Molecular Diagnostics. Background Homologous...
Early Toxicity With Moderately Hypofractionated vs Stereotactic Body Radiotherapy in Prostate Cancer
In an analysis from a phase III trial (PACE-C) reported in The Lancet Oncology, Tree et al compared early toxicity rates with intensity-modulated moderately hypofractionated radiotherapy (MHRT) vs stereotactic body radiotherapy (SBRT) in patients with intermediate- and high-risk prostate...
Perioperative Pembrolizumab in Locally Advanced Head and Neck Cancer
In an interim analysis of a phase III trial (KEYNOTE-689) reported in The New England Journal of Medicine, Uppaluri et al examined the survival benefit of adding perioperative pembrolizumab to standard care in patients with locally advanced head and neck squamous cell carcinoma. Study Details In...
Breast Cancer: New Study Finds Survivors May Face Lower Risk of Alzheimer Dementia
Breast cancer survivors may have a slightly lower risk of developing Alzheimer dementia compared with cancer-free individuals, according to the results of a study published by Jeong et al in JAMA Network Open. “The risk of Alzheimer dementia is a crucial aspect of overall well-being among breast...
New Data Show Nearly 50% of All Cancer Deaths Worldwide Are Attributable to Modifiable Risk Factors
New reporting in The Cancer Atlas, Fourth Edition, showed that an estimated 50% of all cancer deaths worldwide are attributed to modifiable risk factors, including tobacco and alcohol use, infections, excess body weight, unhealthy diet, physical inactivity, ultraviolet radiation, environmental...
GPC3-Targeted ImmunoPET Helps Detect Earlier-Stage Hepatocellular Carcinoma
A novel immuno–positron-emission tomography (immunoPET) imaging agent targeting GPC3 demonstrated high sensitivity and specificity in detecting GPC3-positive hepatocellular carcinoma (HCC) tumors, including those under 1 cm, according to the results of a pilot clinical study presented at the...
Adding the Hepcidin Mimetic Rusfertide to the Standard of Care Yields Benefits in Polycythemia Vera
In patients with polycythemia vera requiring frequent phlebotomies, the investigational hepcidin mimetic rusfertide, given as a weekly subcutaneous injection, more than doubled the clinical response rate and significantly improved quality of life in the global phase III VERIFY study.1 These...
The Ohio State Appoints Christian Rolfo, MD, PhD, MBA, to Lead Division of Medical Oncology
Christian Rolfo, MD, PhD, MBA, has been appointed Director of the Division of Medical Oncology at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James). He will assume this position on August 15. Dr. Rolfo will ...
Malignant Hematology Expert and Medicare Reimbursement Advocate, Samuel M. Silver, MD, PhD, FRCP, FASCO, MACP, Dies at 74
The ASCO Post would like to pay tribute to Samuel M. Silver, MD,PhD, FRCP, FASCO, MACP, who died on August 14, 2024, at the age of 74. Dr. Silver was renowned in the hematology and oncology community and a respected member of the editorial advisory board of The ASCO Post. Additionally, he served...
